FindMyRecallSubscribe
Class I: serious health riskTerminated

Cubist Pharmaceuticals Cubicin Recall

CUBICIN (daptomycin for injection) 500 mg, For Intravenous Use Only, Rx Only, Single u…

Cubist Pharmaceuticals, Inc. · Lexington, MA

Risk level
Class I
Reported by FDA
Nov 5, 2014
Recall ID
D-0229-2015
Check your lot numberHow we source this data

Summary

Cubist Pharmaceuticals recalled Cubicin starting Aug 8, 2014. The FDA classified it as Class I (serious health risk) and published enforcement report D-0229-2015 on Nov 5, 2014. Reason: Presence of Particulate Matter: Foreign particulate matter (tiny black specs) were observed at the bottom of the vial following reconstitution. Status: Terminated.

Why it was recalled

Presence of Particulate Matter: Foreign particulate matter (tiny black specs) were observed at the bottom of the vial following reconstitution.

Product description

CUBICIN (daptomycin for injection) 500 mg, For Intravenous Use Only, Rx Only, Single use Vial, Manufactured for: Cubist Pharmaceuticals Inc., Lexington, MA 02421, USA, NDC 67919-011-01

Lot numbers, UPCs & expiration codes

Lot #'s: CDC203, Exp 12/2015; CDC207, Exp 01/2016; CDC213, Exp 02/2016; CDC217, Exp 03/2016; CDC226, Exp 04/2016; CDC234, CDC235, Exp 05/2016; CDC243, CDC246, Exp 07/2016.

Where it was sold

Nationwide and Puerto Rico.

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0229-2015
Classification
Class I
Status
Terminated
Recall initiated
Aug 8, 2014
FDA report date
Nov 5, 2014
Quantity
371,879 Vials
Recall type
Voluntary: Firm initiated
Recalling firm
Cubist Pharmaceuticals, Inc.

Original FDA data

Every field from FDA enforcement report D-0229-2015, exactly as published.

Show all FDA fields
City
Lexington
State
MA
Status
Terminated
Country
United States
Event ID
67180
Address
65 Hayden Ave
Code information
Lot #'s: CDC203, Exp 12/2015; CDC207, Exp 01/2016; CDC213, Exp 02/2016; CDC217, Exp 03/2016; CDC226, Exp 04/2016; CDC234, CDC235, Exp 05/2016; CDC243, CDC246, Exp 07/2016.
Postal code
02421-7994
Report date
Nov 5, 2014
Product type
Drugs
Recall number
D-0229-2015
Classification
Class I
Recalling firm
Cubist Pharmaceuticals, Inc.
Product quantity
371,879 Vials
Termination date
Jul 29, 2016
Reason for recall
Presence of Particulate Matter: Foreign particulate matter (tiny black specs) were observed at the bottom of the vial following reconstitution.
Voluntary / mandated
Voluntary: Firm initiated
Product description
CUBICIN (daptomycin for injection) 500 mg, For Intravenous Use Only, Rx Only, Single use Vial, Manufactured for: Cubist Pharmaceuticals Inc., Lexington, MA 02421, USA, NDC 67919-011-01
Distribution pattern
Nationwide and Puerto Rico.
Recall initiation date
Aug 8, 2014
Initial firm notification
Press Release
Center classification date
Oct 30, 2014

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0229-2015, published Nov 5, 2014. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls